• DADS = Dear/Darling Dads (plural of "DD" for dad)
• DD = Dear/Darling Daughter (or Dear/Darling Dad in some contexts)

DADS - Distal Acquired Demyelinating Symmetric Neuropathy

What Is DADS?

• Symmetric, distal-predominant sensory or sensorimotor deficits
• Demyelinating pattern on electrodiagnostic studies
• Predominantly length-dependent distribution (unlike classic CIDP, which involves proximal and distal equally)
• Frequent sensory ataxia
• Strong association with IgM monoclonal gammopathy (~two-thirds of cases)

Key Features

• Bradley & Daroff's Neurology in Clinical Practice
• Harrison's Principles of Internal Medicine 22E (2025)

Differential Diagnosis (DD) of DADS

1. Classic CIDP

• Proximal AND distal weakness/sensory loss (not distal-only)
• Conduction block more prominent
• Responds well to corticosteroids, IVIG, plasmapheresis
• No IgM gammopathy typically
• Key distinction: DADS is distal-symmetric; CIDP is generalized

2. IgM MGUS Neuropathy (Anti-MAG Neuropathy)

• DADS and IgM MGUS neuropathy overlap significantly - they may be the same entity
• Anti-myelin-associated glycoprotein (anti-MAG) antibodies are present in majority
• Slowly progressive, predominantly sensory, distal, with ataxia
• Responds to rituximab more than IVIG/steroids
• Goldman-Cecil Medicine: "Patients with IgM MGUS-associated peripheral neuropathy have a slowly progressive distal acquired demyelinating symmetric (DADS) presentation"

3. POEMS Syndrome (Osteosclerotic Myeloma)

• Polyneuropathy + Organomegaly + Endocrinopathy + M-protein + Skin changes
• IgG or IgA M-protein (not IgM)
• Sclerotic bone lesions on imaging
• VEGF elevated
• More motor than sensory involvement

4. AL Amyloidosis Neuropathy

• Length-dependent, painful, small-fiber predominant
• IgG or IgA light chains; κ light chain common
• Congo red-positive deposits on biopsy
• Autonomic dysfunction often prominent (unlike DADS)

5. Waldenström's Macroglobulinemia

• IgM M-protein (like DADS-associated IgM MGUS)
• But >10% clonal lymphoplasmacytic cells on bone marrow biopsy
• Hyperviscosity symptoms, lymphadenopathy, hepatosplenomegaly

6. Cryoglobulinemia (Type I or II)

• Associated with hepatitis C or lymphoproliferative disease
• Vasculitic/axonal neuropathy rather than demyelinating
• Palpable purpura, Raynaud's phenomenon, cold sensitivity

7. MMN (Multifocal Motor Neuropathy)

• Asymmetric, purely motor, with conduction block
• Anti-GM1 antibodies
• No sensory involvement - key distinguishing feature from DADS

8. CMT (Hereditary Demyelinating Neuropathy / Charcot-Marie-Tooth)

• Demyelinating NCS pattern, but symmetric, distal
• Family history, pes cavus, hammer toes
• Onset in childhood/young adulthood
• Uniform slowing on NCS (not acquired), no M-protein

9. Diabetic Polyneuropathy

• Length-dependent sensory neuropathy, but usually axonal
• Demyelinating features can occur and may mimic DADS
• Hyperglycemia + metabolic syndrome history

10. Paraneoplastic Neuropathy

• Associated with underlying malignancy (e.g., colorectal carcinoma - per Ayyappan et al., PMID 25387811)
• Onconeuronal antibodies (anti-Hu, anti-Yo, etc.)
• More subacute onset

Workup to Narrow the DD

Treatment Note

• IgM MGUS-associated DADS: Rituximab or IVIG preferred; responds poorly to corticosteroids alone
• Non-IgM DADS (true CIDP variant): May respond to IVIG or plasmapheresis/prednisone
• Classic CIDP treatments (corticosteroids, IVIG) are less effective in the IgM-DADS subtype
• Bradley & Daroff's Neurology in Clinical Practice
• Harrison's Principles of Internal Medicine 22E (2025), McGraw Hill
• Goldman-Cecil Medicine

Recent Clinical Guidelines & Evidence on DADS Neuropathy Management

The Authoritative Guideline: 2021 EAN/PNS Consensus (Current Standard)

• DADS is now formally classified as one of four recognized CIDP variants (alongside sensory CIDP, MADSAM, and motor CIDP)
• The guidelines strongly advise the following workup for all DADS/CIDP variant presentations:
  • Electrodiagnostic studies (NCS/EMG)
  • Serum and urine monoclonal protein immunofixation (not just protein electrophoresis)
  • Fasting blood glucose
  • Complete blood count, renal function, liver function
• DADS and MADSAM variants are explicitly noted to respond less well to standard immunotherapy than typical CIDP

Treatment Framework for DADS (2021 EAN/PNS + Current Evidence)

Step 1 - Establish the Subtype (IgM vs. Non-IgM)

Step 2 - First-Line Therapies

For IgM-DADS / Anti-MAG Neuropathy:

• Rituximab (anti-CD20 B-cell depleting agent) is the most widely used treatment
  • Two RCTs (RIMAG, RANKING trials) failed to meet their primary endpoints
  • However, a meta-analysis of these two RCTs demonstrated meaningful improvement in disability at 8-12 months [PMID 39658134, Min et al., JNNP 2025]
  • Standard dose: 375 mg/m² x 4 weekly infusions, or 1000 mg x 2 doses 2 weeks apart
  • Response is slow - reassess at 6-12 months
• IVIG and plasma exchange: unproven long-term benefit, may provide short-term effects only
• Cytotoxic agents (chlorambucil, cyclophosphamide, fludarabine): used historically, no strong evidence base

For Non-IgM DADS (true CIDP variant):

• IVIG: first-line; response is better than IgM-DADS but still suboptimal
• Corticosteroids (prednisone): can be used but response less robust than typical CIDP
• Plasma exchange: third-line; evidence extrapolated from typical CIDP

Step 3 - Refractory DADS (Second & Third Line)

• ~25% of CIDP-spectrum patients (including DADS) are refractory to first-line therapies
• Re-evaluate diagnosis before escalating - ensure anti-MAG status is known, rule out mimic disorders
• Second-line options being studied/used:
  • Mycophenolate mofetil (MMF) - T and B cell targeted
  • Autologous hematopoietic stem cell transplantation (HSCT) - for severe, refractory cases
  • Bortezomib (proteasome inhibitor targeting plasma cells) - small case series showing stabilization in 6/10 refractory patients
  • Bruton's tyrosine kinase (BTK) inhibitors - two ongoing trials as of 2025 [PMID 39658134]
  • Lenalidomide - a recent trial was stopped early due to high rate of venous thromboembolism

Step 4 - Novel/Emerging Therapies (2023-2025)

Outcome Measures - A Known Challenge

Key Recent References